

Specialty Pharmacy Program

Caprelsa[®] (vandetanib)

DESCRIPTION

Caprelsa is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Caprelsa is a tyrosine kinase inhibitor that inhibits the activity of RET, epidermal growth factor receptors, vascular endothelial growth factor receptors, and other kinases.

APPROVAL DURATION

Approval duration: 1 year

APPROVAL CRITERIA

Caprelsa will be approved if the patient meets the following criteria:

- I. Patient has a diagnosis of medullary thyroid cancer **AND**
- II. Thyroid cancer is symptomatic or progressive **AND**
- III. Thyroid cancer is unresectable locally advanced or metastatic **AND**
- IV. Patient does not have hypocalcemia, hypokalemia, or hypomagnesemia **OR**
- V. Electrolyte disorders will be corrected prior to Caprelsa administration **AND**
- VI. Patient does not have long QT syndrome **AND**
- VII. ECG will be monitored according to recommendations provided in the prescribing information for Caprelsa **AND**
- VIII. Patients who are taking QT-prolonging drugs will have ECG monitored more frequently than recommended in the prescribing information for patients who are not receiving QT-prolonging drugs.